XML 22 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Cash flows from operating activities:      
Net income (loss) $ 10,101 $ 3,288  
Adjustments for noncash items:      
Depreciation 5,086 6,252  
Amortization of identifiable intangibles 440 464  
Reduction of right-of-use lease asset 529 610  
Deferred income taxes 407 623  
Accrued pension and post-retirement benefits 80 54  
Stock-based compensation expense 472 686  
Gain (loss) on the sale of divested business (9,657) 0 $ 74,900
Changes in assets and liabilities:      
Accounts and other receivables (14,931) (5,337)  
Inventories (17,513) (5,481)  
Income taxes recoverable/payable (71) (580)  
Prepaid expenses and other 7,174 1,890  
Accounts payable and accrued expenses 12,687 (10,306)  
Lease liability (616) (689)  
Pension and postretirement benefit plan contributions (152) (158)  
Other, net 958 965  
Net cash provided by (used in) operating activities (5,006) (7,719)  
Cash flows from investing activities:      
Capital expenditures (2,957) (2,461)  
Proceeds from the sale of Terphane 9,835 0  
Proceeds from the sale of assets 0 83  
Net cash provided by (used in) investing activities 6,878 (2,378)  
Cash flows from financing activities:      
Borrowings 33,750 179,248  
Debt principal payments (39,047) (177,240)  
Net cash provided by (used in) financing activities (5,297) 2,008  
Effect of exchange rate changes on cash 20 (574)  
Increase (decrease) in cash and cash equivalents (3,405) (8,663)  
Cash and cash equivalents at beginning of period 7,062 13,455 13,455
Cash and cash equivalents at end of period $ 3,657 $ 4,792 $ 7,062